252 related articles for article (PubMed ID: 36817448)
1. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
Clubb JHA; Kudling TV; Girych M; Haybout L; Pakola S; Hamdan F; Cervera-Carrascon V; Hemmes A; Grönberg-Vähä-Koskela S; Santos JM; Quixabeira DCA; Basnet S; Heiniö C; Arias V; Jirovec E; Kaptan S; Havunen R; Sorsa S; Erikat A; Schwartz J; Anttila M; Aro K; Viitala T; Vattulainen I; Cerullo V; Kanerva A; Hemminki A
Front Immunol; 2023; 14():1060540. PubMed ID: 36817448
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
Clubb JHA; Kudling TV; Heiniö C; Basnet S; Pakola S; Cervera Carrascón V; Santos JM; Quixabeira DCA; Havunen R; Sorsa S; Zheng V; Salo T; Bäck L; Aro K; Tulokas S; Loimu V; Hemminki A
Front Immunol; 2022; 13():794251. PubMed ID: 35355980
[TBL] [Abstract][Full Text] [Related]
3. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
Phillips LM; Li S; Gumin J; Daou M; Ledbetter D; Yang J; Singh S; Parker Kerrigan BC; Hossain A; Yuan Y; Gomez-Manzano C; Fueyo J; Lang FF
Neuro Oncol; 2021 Nov; 23(11):1911-1921. PubMed ID: 34059921
[TBL] [Abstract][Full Text] [Related]
4. New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.
Spencer JF; Sagartz JE; Wold WS; Toth K
Cancer Gene Ther; 2009 Dec; 16(12):912-22. PubMed ID: 19478829
[TBL] [Abstract][Full Text] [Related]
5. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors.
Thomas MA; Spencer JF; Wold WS
Methods Mol Med; 2007; 130():169-83. PubMed ID: 17401172
[TBL] [Abstract][Full Text] [Related]
6. Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1.
Havunen R; Kalliokoski R; Siurala M; Sorsa S; Santos JM; Cervera-Carrascon V; Anttila M; Hemminki A
Cells; 2021 Jan; 10(2):. PubMed ID: 33513935
[TBL] [Abstract][Full Text] [Related]
7. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.
Thomas MA; Spencer JF; La Regina MC; Dhar D; Tollefson AE; Toth K; Wold WS
Cancer Res; 2006 Feb; 66(3):1270-6. PubMed ID: 16452178
[TBL] [Abstract][Full Text] [Related]
8. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity.
Mei S; Peng S; Vong EG; Zhan J
Int Immunopharmacol; 2024 Feb; 128():111579. PubMed ID: 38278066
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer.
LaRocca CJ; Han J; Gavrikova T; Armstrong L; Oliveira AR; Shanley R; Vickers SM; Yamamoto M; Davydova J
Surgery; 2015 May; 157(5):888-98. PubMed ID: 25731784
[TBL] [Abstract][Full Text] [Related]
10. Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting.
Siurala M; Vähä-Koskela M; Havunen R; Tähtinen S; Bramante S; Parviainen S; Mathis JM; Kanerva A; Hemminki A
Oncoimmunology; 2016 May; 5(5):e1136046. PubMed ID: 27467954
[TBL] [Abstract][Full Text] [Related]
11. Syrian hamster tumor model to study oncolytic Ad5-based vectors.
Dhar D; Toth K; Wold WS
Methods Mol Biol; 2012; 797():53-63. PubMed ID: 21948468
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.
Santos JM; Cervera-Carrascon V; Havunen R; Zafar S; Siurala M; Sorsa S; Anttila M; Kanerva A; Hemminki A
Mol Ther; 2018 Sep; 26(9):2243-2254. PubMed ID: 30017877
[TBL] [Abstract][Full Text] [Related]
13. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
[TBL] [Abstract][Full Text] [Related]
14. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.
Lichtenstein DL; Spencer JF; Doronin K; Patra D; Meyer JM; Shashkova EV; Kuppuswamy M; Dhar D; Thomas MA; Tollefson AE; Zumstein LA; Wold WS; Toth K
Cancer Gene Ther; 2009 Aug; 16(8):644-54. PubMed ID: 19197324
[TBL] [Abstract][Full Text] [Related]
15. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model.
Nistal-Villan E; Bunuales M; Poutou J; Gonzalez-Aparicio M; Bravo-Perez C; Quetglas JI; Carte B; Gonzalez-Aseguinolaza G; Prieto J; Larrea E; Hernandez-Alcoceba R
Mol Cancer; 2015 Dec; 14():210. PubMed ID: 26671477
[TBL] [Abstract][Full Text] [Related]
16. An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage.
Pakola S; Quixabeira DCA; Kudling TV; Clubb JHA; Grönberg-Vähä-Koskela S; Basnet S; Jirovec E; Arias V; Haybout L; Heiniö C; Santos JM; Cervera-Carrascon V; Havunen R; Anttila M; Hemminki A
Front Immunol; 2023; 14():1171083. PubMed ID: 37475863
[TBL] [Abstract][Full Text] [Related]
17. Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.
Cervera-Carrascon V; Quixabeira DCA; Santos JM; Havunen R; Zafar S; Hemminki O; Heiniö C; Munaro E; Siurala M; Sorsa S; Mirtti T; Järvinen P; Mildh M; Nisen H; Rannikko A; Anttila M; Kanerva A; Hemminki A
Oncoimmunology; 2020 May; 9(1):1761229. PubMed ID: 32923123
[TBL] [Abstract][Full Text] [Related]
18. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.
Ying B; Toth K; Spencer JF; Meyer J; Tollefson AE; Patra D; Dhar D; Shashkova EV; Kuppuswamy M; Doronin K; Thomas MA; Zumstein LA; Wold WS; Lichtenstein DL
Cancer Gene Ther; 2009 Aug; 16(8):625-37. PubMed ID: 19197322
[TBL] [Abstract][Full Text] [Related]
19. Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters.
Bortolanza S; Alzuguren P; Buñuales M; Qian C; Prieto J; Hernandez-Alcoceba R
Hum Gene Ther; 2007 Aug; 18(8):681-90. PubMed ID: 17658991
[TBL] [Abstract][Full Text] [Related]
20. A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity.
Tysome JR; Li X; Wang S; Wang P; Gao D; Du P; Chen D; Gangeswaran R; Chard LS; Yuan M; Alusi G; Lemoine NR; Wang Y
Clin Cancer Res; 2012 Dec; 18(24):6679-89. PubMed ID: 23091113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
